29 research outputs found
The interplay between functioning problems and symptoms in first episode of psychosis: an approach from network analysis
The relationship between psychotic symptoms and global measures of functioning has been widely studied. No previous study has assessed so far the interplay between specific clinical symptoms and particular areas of functioning in first-episode psychosis (FEP) using network analysis methods. A total of 191 patients with FEP (age 24.45 ± 6.28 years, 64.9% male) participating in an observational and longitudinal study (AGES-CM) comprised the study sample. Functioning problems were assessed with the WHO Disability Assessment Schedule (WHODAS), whereas the Positive and Negative Syndrome Scale (PANSS) was used to assess symptom severity. Network analysis were conducted with the aim of analysing the patterns of relationships between the different dimensions of functioning and PANSS symptoms and factors at baseline. According to our results, the most important nodes were “conceptual disorganization”, “emotional withdrawal”, “lack of spontaneity and flow of conversation”, “delusions”, “unusual thought content”, “dealing with strangers” and “poor rapport”. Our findings suggest that these symptoms and functioning dimensions should be prioritized in the clinical assessment and management of patients with FEP. These areas may also become targets of future early intervention strategies, so as to improve quality of life in this populationThis work was supported by the Madrid Regional Government (R&D
activities in Biomedicine (grant number S2017/BMD-3740 - AGES-CM
2-CM)) and Structural Funds of the European Union. Ana Izquierdo’s
work is supported by the PFIS predoctoral program (FI17/00138) from
the Instituto de Salud Carlos III (Spain) and co-funded by the European
Union (ERDF/ESF, "A way to make Europe”/ “Investing in your future”)
and The Biomedical Research Foundation of La Princesa University Hospital.
Angela Ib´a˜nez thanks the support of CIBERSAM and of the Spanish
Ministry of Science, Innovation and Universities. Instituto de Salud
Carlos III (PI16/00834 and PI19/01295) co-financed by ERDF Funds
from the European Commission. Covadonga M. Díaz-Caneja holds a
Juan Rod´es Grant from Instituto de Salud Carlos III (JR19/00024). Celso
Arango was supported by the Spanish Ministry of Science and Innovation.
Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/
024), co-financed by ERDF Funds from the European Commission, “A
way of making Europe”, CIBERSAM. Madrid Regional Government
(B2017/BMD-3740 AGES-CM-2), European Union Structural Funds.
European Union Seventh Framework Program under grant agreements
FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-
2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-
2.2.1-2-602478 (Project METSY); and European Union H2020 Program
under the Innovative Medicines Initiative 2 Joint Undertaking
(grant agreement No 115916, Project PRISM, and grant agreement No
777394, Project AIMS-2-TRIALS), Fundaci´on Familia Alonso, Fundaci´on
Alicia Koplowitz and Fundaci´on Mutua Madrile˜n
Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality
Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting
26 p.-6 fig.-1 tab.-1 graph. abst.There has been an intense focus to uncover the molecular mechanisms by which fasting triggers the adaptive cellular responses in the major organs of the body. Here, we show that in mice, hepatic S-adenosylmethionine (SAMe)—the principal methyl donor—acts as a metabolic sensor of nutrition to fine-tune the catabolic-fasting response by modulating phosphatidylethanolamine N-methyltransferase (PEMT) activity, endoplasmic reticulum-mitochondria contacts, β-oxidation, and ATP production in the liver, together with FGF21-mediated lipolysis and thermogenesis in adipose tissues. Notably, we show that glucagon induces the expression of the hepatic SAMe-synthesizing enzyme methionine adenosyltransferase α1 (MAT1A), which translocates to mitochondria-associated membranes. This leads to the production of this metabolite at these sites, which acts as a brake to prevent excessive β-oxidation and mitochondrial ATP synthesis and thereby endoplasmic reticulum stress and liver injury. This work provides important insights into the previously undescribed function of SAMe as a new arm of the metabolic adaptation to fasting.M.V.-R. is supported by Proyecto PID2020-119486RB-100 (funded by MCIN/AEI/10.13039/501100011033), Gilead Sciences International Research Scholars Program in Liver Disease, Acción Estratégica Ciberehd Emergentes 2018 (ISCIII), Fundación BBVA, HORIZON-TMA-MSCA-Doctoral Networks 2021 (101073094), and Redes de Investigación 2022 (RED2022-134485-T). M.L.M.-C. is supported by La CAIXA Foundation (LCF/PR/HP17/52190004), Proyecto PID2020-117116RB-I00 (funded by MCIN/AEI/10.13039/501100011033), Ayudas Fundación BBVA a equipos de investigación científica (Umbrella 2018), and AECC Scientific Foundation (Rare Cancers 2017). A.W. is supported by RTI2018-097503-B-I00 and PID2021-127169OB-I00, (funded by MCIN/AEI/10.13039/501100011033) and by “ERDF A way of making Europe,” Xunta de Galicia (Ayudas PRO-ERC), Fundación Mutua Madrileña, and European Community’s H2020 Framework Programme (ERC Consolidator grant no. 865157 and MSCA Doctoral Networks 2021 no. 101073094). C.M. is supported by CIBERNED. P.A. is supported by Ayudas para apoyar grupos de investigación del sistema Universitario Vasco (IT1476-22), PID2021-124425OB-I00 (funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe,” MCI/UE/ISCiii [PMP21/00080], and UPV/EHU [COLAB20/01]). M.F. and M.G.B. are supported by PID2019-105739GB-I00 and PID2020-115472GB-I00, respectively (funded by MCIN/AEI/10.13039/501100011033). M.G.B. is supported by Xunta de Galicia (ED431C 2019/013). C.A., T.L.-D., and J.B.-V. are recipients of pre-doctoral fellowships from Xunta de Galicia (ED481A-2020/046, ED481A-2018/042, and ED481A 2021/244, respectively). T.C.D. is supported by Fundación Científica AECC. A.T.-R. is a recipient of a pre-doctoral fellowship from Fundación Científica AECC. S.V.A. and C.R. are recipients of Margarita Salas postdoc grants under the “Plan de Recuperación Transformación” program funded by the Spanish Ministry of Universities with European Union’s NextGeneration EU funds (2021/PER/00020 and MU-21-UP2021-03071902373A, respectively). T.C.D., A.S.-R., and M.T.-C. are recipients of Ayuda RYC2020-029316-I, PRE2019/088960, and BES-2016/078493, respectively, supported by MCIN/AEI/10.13039/501100011033 and by El FSE invierte en tu futuro. S.L.-O. is a recipient of a pre-doctoral fellowship from the Departamento de Educación del Gobierno Vasco (PRE_2018_1_0372). P.A.-G. is recipient of a FPU pre-doctoral fellowship from the Ministry of Education (FPU19/02704). CIC bioGUNE is supported by Ayuda CEX2021-001136-S financiada por MCIN/AEI/10.13039/501100011033. A.B.-C. was funded by predoctoral contract PFIS (FI19/00240) from Instituto de Salud Carlos III (ISCIII) co-funded by Fondo Social Europeo (FSE), and A.D.-L. was funded by contract Juan Rodés (JR17/00016) from ISCIII. A.B.-C. is a Miguel Servet researcher (CPII22/00008) from ISCIII.Peer reviewe
Uso y gestión de objetos de aprendizaje en la web
El proyecto “ Uso y gestión de objetos de aprendizaje en un entorno Web” se ha
desarrollado en la asignatura Sistemas Informáticos. Tiene como objetivo el desarrollo de la
versión 0.0 del Museo Virtual García Santesmases de la Facultad de Informática de la
Universidad Complutense de Madrid.
Las características más importantes que se encuentran implementadas en la
aplicación se centran en la necesidad de utilizar todo el material del que dispone el museo
con fines educativos. Esto implica que todos los “objetos” del museo estén organizados y
relacionados para facilitar la visita e investigación de alumnos, profesores e investigadores.
Otras de las características más importantes que se ha tratado es proporcionar mecanismos al
museo para que los usuarios accedan a la información sin necesidad de estar en el museo, y
la transportabilidad de la información que compone el museo entre sistemas de
características similares.
[ABSTRACT]
The proyect called “Use and Management of Learning Objects in the Web” has been
developed into the subject “Sistemas Informáticos”. The main target is the development of
the fisrt version of the “Virtual García Santesmases Museum” located at the School of
Computer Science of the Complutense University of Madrid.
The most important features implemented in the aplication are related to use all the
available data of the Museum for educational purposes.
This means that the “objects” must be organized and bound to provide the visit and
research of the student, professors, and researchers.
In addition, the museum supplies the users with procedures to move data between
systems that understand the same standards used to organize the data
NQO1 gene rs1800566 variant is not associated with risk for multiple sclerosis
Abstract Background A possible role of oxidative stress in the pathogenesis of multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis has been suggested. The detoxification enzyme NAD(P)H dehydrogenase, quinone 1 (NQO1) has been found up-regulated in MS lesions. A previous report described an association between the SNP rs1800566 in the NQO1 gene and the risk for MS in the Greek population. The aim of this study was to replicate a possible influence of the. SNP rs1800566 in the NQO1 gene in the risk for MS in the Spanish Caucasian population. Methods We analyzed allelic and genotypic frequency of NQO1 rs1800566 in 290 patients with MS and 310 healthy controls, using TaqMan Assays. Results NQO1 rs1800566 allelic and genotypic frequencies did not differ significantly between MS patients and controls, and were unrelated with age of onset of MS, gender, and clinical type of MS. Conclusions Our results indicate that NQO1 rs1800566 does not have an effect on MS disease risk.This work was supported in part by Grants PI12/00241, PI12/00324 and RETICS RD12/0013/0002 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain, and GR10068 from Junta de Extremadura, Spain. Financed in part with FEDER funds from the European Union.Peer Reviewe
LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis
Background: Some recent experimental data suggest a possible role of LINGO-1 in the pathogenesis of multiple sclerosis (MS). In an attempt to identify genetic biomarkers related to MS susceptibility, we genotyped two common SNPs in the LINGO1 gene which have been associated to other neurological conditions, in patients with MS and in healthy subjects. These SNPs are linked to several SNPs within the LINGO1 gene, especially in individuals of Oriental or Caucasian descent.Methods: We analyzed the allelic and genotype frequency of two LINGO1 variants (rs9652490 and rs11856808) in 293 patients with MS and 318 healthy controls, using KASPar assays.Results: LINGO1 rs9652490 and rs11856808 allelic and genotype frequencies did not differ significantly between MS patients and controls. The minor allele frequencies for rs9652490 were 0.171 (95% CI = 0.140-0.201) and 0.167 (95% CI = 0.138-0.196 for cases and controls respectively (p = 0.853). For rs11856808 the minor allele frequencies were 0.317 (95% CI = 0.280-0.355) and 0.310 (95% CI = 0.274-0.346) for cases and controls, respectively (p = 0.773). Allele and genotype frequencies were unrelated with the age of onset of MS, gender, and clinical course of MS. In addition, haplotype analyses did not reveal any putative risk related to haplotypes.Conclusions: These results suggest that LINGO1 rs9652490 and rs11856808 polymorphisms are not related with risk for MS. This study adds to other published evidence indicating that, to date, the LINGO1 SNPs studied here could be useful risk biomarkers of developing essential tremor, but not other movement disorders. © 2013 García-Martín et al.; licensee BioMed Central Ltd.Instituto de Salud Carlos III PS09/00943, PS09/00469, PI12/00241, PI12/00324 and RETICS RD12/0013/0002 from Fondo de Investigación Sanitaria; Spanish Ministry of Science and Innovation (SAF2006-10126 and SAF2010-22329-C02-01); Junta de Extremadura (GR10068); European Union (FEDER)Peer Reviewe
MAPT gene rs1052553 variant is not associated with the risk for multiple sclerosis
Background/Objectives: Some experimental data suggest a possible role of tau protein in the pathogenesis of multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis. The aim of this study was to investigate a possible influence of the SNP rs1052553 in the MAPT gene in the risk for relapsing bout onset (relapsing-remitting and secondary progressive) MS. Methods: We analyzed the allelic and genotype frequency of MAPT rs1052553, which has been associated with some neurodegenerative diseases, in 259 patients with relapsing bout onset MS and 291 healthy controls, using TaqMan Assays. Results: MAPT rs1052553 allelic and genotype frequencies did not differ significantly between relapsing bout onset MS patients and controls, and were unrelated with the age of onset of MS or gender. Conclusions: These results suggest that MAPT rs1052553 polymorphism is not related with the risk for relapsing bout onset MS. © 2013 American Society for Histocompatibility and Immunogenetics.Junta de Extremadura, Spain (GR10068); European Union (FEDER)Peer Reviewe
Heme oxygenase-1 and 2 common genetic variants and risk for multiple sclerosis
Varios neurotransmisores, neuropatológicos, y los datos experimentales sugieren un posible papel del estrés oxidativo en la etiopatogenia de la esclerosis múltiple (MS). Hemo-oxygenases(HMOX) son un importante mecanismo de defensa contra el estrés oxidativo y HMOX1 está sobre expresado en el cerebro y la médula espinal de los pacientes de esclerosis múltiple y en la encefalomielitis autoinmune experimental (EAE). Hemos analizado si los polimorfismos comunes que afectan a la HMOX1 y HMOX2 genes están relacionados con el riesgo de desarrollar MS. Se analizó la distribución de genotipos y frecuencias alélicas de los HMOX1 rs2071746, HMOX1 rs2071747, HMOX2 rs2270363 y rs1051308 HMOX2 SNPs, así como la presencia de variaciones de número de copia (CNVs) de estos genes en 292 sujetos ms y 533 controles sanos, utilizando ensayos TaqMan. Las frecuencias de HMOX genotipo AA1051308rs2 y Rs2 HMOX1051308A y HMOX1 rs2071746Un alelos MS fueron superiores en los pacientes que en los controles, aunque solamente del SNP rs1051308 HMOX2 en el hombre seguía siendo tan significativas después de la corrección para comparaciones múltiples. Ninguno de los polimorfismos estudiados se relaciona con la edad al inicio de la enfermedad o con el fenotipo de MS. El presente estudio sugiere una débil asociación entre el polimorfismo rs1051308 HMOX2 y el riesgo de desarrollar MS en español los hombres caucásicos y una tendencia hacia una asociación entre el HMOX1 rs2071746A y MS riesgo.Several neurochemical, neuropathological, and experimental data suggest a possible role of oxidative stress in the ethiopathogenesis of multiple sclerosis (MS). Heme-oxygenases (HMOX) are an important defensive mechanism against oxidative stress, and HMOX1 is overexpressed in the brain and spinal cord of MS patients and in experimental autoimmune encephalomyelitis(EAE). We analyzed whether common polymorphisms affecting the HMOX1 and HMOX2 genes are related with the risk to develop MS. We analyzed the distribution of genotypes and allelic frequencies of the HMOX1 rs2071746, HMOX1 rs2071747, HMOX2 rs2270363, and HMOX2 rs1051308 SNPs, as well as the presence of Copy number variations(CNVs) of these genes in 292 subjects MS and 533 healthy controls, using TaqMan assays. The frequencies of HMOX2 rs1051308AA genotype and HMOX2 rs1051308A and HMOX1 rs2071746A alleles were higher in MS patients than in controls, although only that of the SNP HMOX2 rs1051308 in men remained as significant after correction for multiple comparisons. None of the studied polymorphisms was related to the age at disease onset or with the MS phenotype. The present study suggests a weak association between HMOX2 rs1051308 polymorphism and the risk to develop MS in Spanish Caucasian men and a trend towards association between the HMOX1 rs2071746A and MS risk.Trabajo patrocinado por:
Instituto de Salud Carlos III. Fondo de Investigación Sanitaria. Becas PI12/00241, PI12/00324 y RETICS RD12/0013/0002
Junta de Extremadura y Fondos FEDER. Ayuda GR15026peerReviewednotPeerReviewe
Gene-gene interaction between the HLA-DRB1*1501 tagging SNP (rs3135388), and the VDR gene polymorphisms in patients with MS.
<p>NPV negative predictive value.</p><p>Combinations for all genotypes were analyzed in 302 MS patients and 309 controls. The frequencies shown correspond to the frequencies of a particular combination of VDR genotype within every rs3135388 (HLADRB1*1501) genotype category.</p